3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Breast Neoplasms
597
Stomach Neoplasms
72
Neoplasm Metastasis
56
Neoplasms
35
HER2-positive Breast Cancer
31
Breast Neoplasms, Male
30
Colorectal Neoplasms
28
Brain Neoplasms
23
Carcinoma, Non-Small-Cell Lung
21
Inflammatory Breast Neoplasms
20
Esophageal Neoplasms
20
Pancreatic Neoplasms
13
Triple Negative Breast Neoplasms
12
Lung Neoplasms
11
Endometrial Neoplasms
11
Ovarian Neoplasms
10
Colonic Neoplasms
10
Urinary Bladder Neoplasms
9
Rectal Neoplasms
9
Prostatic Neoplasms
9
Adenocarcinoma
8
Salivary Gland Neoplasms
7
Gallbladder Neoplasms
7
Breast Diseases
7
Biliary Tract Neoplasms
7
Adenocarcinoma Of Esophagus
7
Uterine Cervical Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Sarcoma
6
Pathologic Complete Response
6
Interventions
pembrolizumab
7
Radiotherapy
3
Proton Therapy
3
Interleukin-2
3
Cyclophosphamide
3
spartalizumab
2
fludarabine
2
Rosuvastatin Calcium
2
Paclitaxel
2
Ipilimumab
2
Immune Checkpoint Inhibitors
2
Cetuximab
2
Carboplatin
2
Blood Specimen Collection
2
toripalimab
1
tislelizumab
1
sotorasib
1
peposertib
1
pazopanib
1
patritumab deruxtecan
1
palbociclib
1
osimertinib
1
niraparib
1
neotil
1
necitumumab
1
mirdametinib
1
leronlimab
1
lenvatinib
1
atezolizumab
1
apatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Solid Tumor, Adult
×
Trastuzumab
×
Clear all
NCT04092673
2024-05-21
Zotatifin
Effector Therapeutics
Phase 1/2
Unknown
30 enrolled